Clinical Trial Update: A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) [Phase 2]

View source ↗

Summary

Phase II study evaluating Optune (NovoTTF) with Bevacizumab and Temozolomide in newly diagnosed unresectable glioblastoma; trial terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• OPTUNE
• Temozolomide (Temozolomide)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Cancer of Brain and Nervous System | Phase 2 | Status: TERMINATED | Results posted: 2021-08-10